

Charity registration number 1048066
Company number 3062160

Hinxton Hall Limited
Annual Report and Financial Statements
Year ended 30 September 2008

SATURDAY



AFGLD6S1

A12

24/01/2009

101

COMPANIES HOUSE

Hinxton Hall Limited

Contents

	Page
Directors' Report	2
Independent Auditors' Report	6
Statement of Financial Activities	7
Balance Sheet	8
Notes to the Financial Statements	9
Administrative Details	13

**Hinxton Hall Limited
Directors' Report
For the year ended 30 September 2008**

The Directors of Hinxton Hall Limited ("the Company"), who are also the Trustees of Hinxton Hall Limited, being a charity for the purposes of the Charities Act 1993, present their report and the Financial Statements for the year ended 30 September 2008.

Objects

The objects for which the Company is established are to advance the education of the public, in particular, advancing scientific and medical education and research (and the publication of the useful results of such research) with particular reference to the human genome by the provision of facilities for research, conferences, seminars and training at the Wellcome Trust Genome Campus ("Genome Campus"), which is situated at Hinxton, Cambridgeshire.

Aims

The Company continues to fulfil its charitable objects by undertaking two key charitable activities.

Firstly, the Company provides facilities management services to organisations based at the Genome Campus, the major ones being Genome Research Limited, the European Bioinformatics Institute and the Wellcome Trust Conference Centre. These services include utilities provision, building maintenance, security, cleaning and catering.

Secondly, the Company provides meeting and conference facilities and residential accommodation at the Wellcome Trust Conference Centre on the Genome Campus.

The Company earns income from facilities management charges and conference centre sales and is also funded by grants from the Wellcome Trust.

Achievements and Performance

During the year the Company provided facilities management services to the value of £13.5 million (2007: £12.4 million). This is an increase of £1.1 million from the previous year, due to the increase in the charitable activities at the Genome Campus, the increased size and complexity of the Genome Campus buildings and increases in prices of services.

The Company provides facilities for meetings and conferences that fall within the charitable objects of the Company and which are for public benefit – the Company's "primary purpose". Sales for this activity were £1.7 million (2007: £1.5 million).

To maximise the use of the Wellcome Trust Conference Centre when it is not being utilised for conferences falling within the Company's primary purpose, the Company allows Wellcome Trust Trading Limited ("WTTL"), a wholly-owned non-charitable trading subsidiary of The Wellcome Trust Limited, as Trustee of the Wellcome Trust, to provide conference centre facilities for conferences falling outside the primary purpose of the Company.

Major conferences held by the Company during the year include:

Wellcome Trust Meetings Programme: Crop Genomics; Function Genomics & Systems Biology, Pharmacogenomics, Re-annotating the Malaria Genome, Fundamentals of Clinical Genetics, WT Course on the Bioinformatics of Membrane Proteins, Genomic Disorders, Computational Cell Biology, Ethical & Policy Challenges of Pluripotent Stem Cell, Nicotinic Receptors, Applied Bioinformatics & Public Health Microbiology, Decipher, Signalling to Chromatin, Schistosome Meeting, Genomic Epidemiology of Malaria, High Throughput Cell-Based Biology, Dense Deposit Disease, WT School of Human Genetics, Interactome Networks, Genomic Perspectives to Host Pathogen Interactions, Genome Informatics, Sanger-NKI-CRI Research, International E-Coli Alliance and Viral Vector Vaccines.

Other large meetings and conferences held at the facilities included those sponsored by: ABPI, MRC Dunn Human Nutrition, GlaxoSmithKline, MRC-LMB, Department of Medicine (University of Cambridge), Medimmune, Capita Health Service Partners, ELRIG, CIMR, ME Research UK, NHS East of England, ERBI, European Bioinformatics Institute and MRC.

Hinxton Hall Limited
Directors' Report (continued)
For the year ended 30 September 2008

Future Plans

During 2008/09, facilities management expenditure is expected to remain at a similar level to 2007/08 whilst the Wellcome Trust Conference Centre is expected to provide for a slightly increased level of conferences and meetings within the Company's primary purpose. It is our intention to expand the conference centre facilities at Hinxton Hall and work has commenced in this regard. The expenditure capitalised as at the balance sheet date is shown in Assets in the course of construction in note 7, Tangible Fixed Assets.

Financial Review

The Company reported net income for the year of £346,000 (2007: net expenditure £722,000). This increase is mainly due to the capital grant from the Wellcome Trust, in respect of costs associated with Conference centre expansion. The net movement on resources has been transferred to the restricted and unrestricted reserves as appropriate.

Taxation

There is no corporation tax charge, because all income profits and gains are or have been applied for wholly charitable purposes.

Reserves Policy

The Building and General Funds represent fixed assets, which are funded by grants received from the Wellcome Trust. The funds will be utilised in future periods as depreciation is charged to the funds over the life of the assets.

The Building Fund is a restricted fund and is held for the buildings on the land leased by the Company from the Wellcome Trust. These include Hinxton Hall, a Grade II listed building, the Conference Centre, the Residential Accommodation and the new Shared Services and car park facility. The fund is adjusted each year for building additions and depreciation.

The General Fund is an unrestricted fund and represents the net operational assets of the Company. It is adjusted each year for additions and depreciation.

Expenditure Policy

For planning purposes an annual budget is agreed with the Wellcome Trust and the Genome Campus facilities management customers. The Directors monitor the expenditure of the Company and provide an oversight of the internal budgetary and financial control mechanisms. As the Company receives sufficient funding each year from the Wellcome Trust, a reserve to cover future activities is not required.

Structure, Governance and Management

Company Status

The Company is a charity registered in England with the Charity Commission (Charity registration number 1048066) and a company limited by guarantee and registered in England (Company number 3062160) and is governed by its Memorandum and Articles of Association.

Members

The Company has two members, The Wellcome Trust Limited, as Trustee of the Wellcome Trust, and Genome Research Limited. The Company is a wholly-owned subsidiary of the Wellcome Trust for accounting purposes. The liability of each member is limited to £1.

Board of Directors

The Board of Directors is responsible for ensuring that the charitable objects of the Company are being met. It approves the management structure and operational budgets of the Company. During the financial year, the Board met on two occasions.

The Directors are appointed by the Members of the Company. The performance of the Board is monitored by the Wellcome Trust and any necessary development and training will be advised and managed by the Wellcome Trust.

Hinxton Hall Limited
Directors' Report (continued)
For the year ended 30 September 2008

During the year the Directors were:

J Cooper (*Chairman*)
G Kiff
D Davison

None of the Directors have any beneficial interests in the Company. The Directors do not receive any remuneration for acting as Directors. With the exception of G Kiff, the Directors are also board members of Genome Research Limited and J Cooper is a member of the Wellcome Trust Executive Board.

The Chairman has principal management responsibility for the business activities of the Company with day-to-day responsibility delegated to the Head of Facilities Management and the Head of the Conference Centre.

Other "administrative details" can be found on page 13.

Statement of Directors' Responsibility and Internal Control

Company and charity laws require the Directors to prepare Financial Statements for each financial year, which give a true and fair view of the state of affairs of the Company and of the net incoming resources of the Company for that period. In preparing those Financial Statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the Financial Statements;
- comply with current statutory requirements, the requirements of the charitable Company's governing document and the requirements of the Statement of Recommended Practice: Accounting and Reporting by Charities published in 2005 (SORP); and
- prepare the Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue its activities.

The Directors have overall responsibility for ensuring the Company has appropriate systems of controls, financial and otherwise. They are also responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Company and enables them to ensure that the Financial Statements comply with the Companies Act 1985 and the Charities Act 1993. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reasonable assurances that:

- the charitable company is operating efficiently and effectively;
- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the charitable company for publication is reliable; and
- the charitable company complies with relevant laws and regulations.

The systems of internal control are designed to provide reasonable, but not absolute, assurance against material misstatement or loss. They include:

- an annual budget approved by the Directors;
- regular reporting by the Directors of the financial results;
- delegation of authority and segregation of duties; and
- identification and management of risks.

As far as each Director is aware, there is no relevant audit information of which the Company's auditors are unaware and each Director has taken all the steps that ought to have been taken as a Director in order to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Fixed Assets

The fixed assets of the Company, as set out in note 7 to the Financial Statements, represent the costs, less depreciation, incurred at the Genome Campus. In the opinion of the Directors, there is no significant difference between the market value of the lease of land and buildings from the Wellcome Trust and the net book value of the leasehold land and buildings.

Hinxton Hall Limited
Directors' Report (continued)
For the year ended 30 September 2008

Risk Identification and Mitigation

The major risks to which the Company is exposed have been identified and reviewed by the Directors and systems have been established to mitigate those risks. The Wellcome Trust is committed to financial support of the Company in the provision of facilities management and as a conference centre.

Health and Safety

The Company recognises occupational health and safety as an integral part of its business performance equal to any other operational objective, and is committed to achieving a high level of occupational health and safety performance, exceeding minimum legal requirements wherever reasonably practicable. It acknowledges and accepts that it has a responsibility for the health and safety of persons who may be affected by its business activities, i.e. Wellcome Trust Group employees, contractors, Genome Campus users, visitors and members of the public.

The Senior User Group comprising senior managers from the campus institutes and organisations meet quarterly and review and monitor health and safety on campus. The Directors of the Company receive an annual report on health and safety matters.

The Committee has developed a Health and Safety Policy, which applies to all Genome Campus users. Involvement and consultation of all is actively encouraged through open communication, to gain commitment and full participation in developing health and safety standards on the Genome Campus. Prime responsibility for the management of occupational health and safety rests with the Directors and Senior Management of the Genome Campus. Personal objectives are tailored to expand on individuals' roles in health and safety.

The Health and Safety Policy is supported by a general policy expanding on the organisation and arrangements in place for planning and implementing controls, measuring and reviewing performance and audit of all elements. The Genome Campus is committed to the use of risk assessment as a means of establishing control requirements. Specific policies are developed where necessary to ensure a unified approach. Periodic reviews and audits are conducted to enable continuous improvement.

Employment

The Company has no employees, with services provided being sub-contracted from third parties. The management and administration of the Company is undertaken by staff seconded from The Wellcome Trust Limited, as Trustee of the Wellcome Trust.

Environment

The Company recognises that pollution can be a trigger for those susceptible to certain illnesses and harmful to wildlife and seeks to conduct its activities so as to minimise their environmental impact. The Genome Campus has its own environmental policy. Examples of actions and achievements under the policy include:

- the Genome Campus has a policy to recycle materials wherever it is viable to do so;
- general waste disposal methods have been reviewed to reduce the transport and landfill costs. Transport miles have been reduced, along with the associated emissions;
- the Genome Campus has been awarded the National Clean Air Silver Award by the British Lung Foundation; and
- the Genome Campus has a policy to reduce the amount of pesticides and herbicides used.

Auditors

In accordance with Section 385 of the Companies Act 1985, a resolution proposing that PricewaterhouseCoopers LLP be reappointed as auditors of the Company will be put to the Members.

The Directors' Report was approved by the Board of Directors on 19th November 2008 and signed on its behalf by:



J Cooper
Chairman

**Independent Auditors' Report
To the Members of Hinxton Hall Limited
For the year ended 30 September 2008**

Independent Auditors' Report to the Members of Hinxton Hall Limited

We have audited the Financial Statements of Hinxton Hall Limited for the year ended 30 September 2008 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. These Financial Statements have been prepared under the accounting policies set out therein.

Respective Responsibilities of Directors and Auditors

The Directors also act as trustees for the charitable activities of Hinxton Hall Limited. The responsibilities of the Directors for preparing the Financial Statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the Statement of Directors' Responsibilities.

Our responsibility is to audit the Financial Statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland). This report, including the opinion, has been prepared for and only for the charitable Company's members as a body in accordance with Section 235 of the Companies Act 1985 and for no other purpose. We do not, in giving this opinion, accept or assume any responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

We report to you our opinion as to whether the Financial Statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you whether in our opinion the information given in the Directors' Report is consistent with the Financial Statements.

In addition we report to you if, in our opinion, the charitable Company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding Trustees' remuneration and other transactions is not disclosed.

We read the Directors' Report and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of Audit Opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the Financial Statements. It also includes an assessment of the significant estimates and judgments made by the Trustees in the preparation of the Financial Statements, and of whether the accounting policies are appropriate to the charitable Company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the Financial Statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the Financial Statements.

Opinion

In our opinion

- the Financial Statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the charitable Company's affairs at 30 September 2008 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended; and
- the Financial Statements have been properly prepared in accordance with the Companies Act 1985; and
- the information given in the Directors' Report is consistent with the Financial Statements.


PricewaterhouseCoopers LLP
Chartered Accountants and Registered Auditors
London

16/12/08

Hinxton Hall Limited
Statement of Financial Activities (incorporating income and expenditure account)
For the year ended 30 September 2008

	Note	Restricted Building Fund £'000	Unrestricted General Fund £'000	2008 Total £'000	2007 Total £'000
INCOMING RESOURCES					
Charitable activities					
Provision of Facilities Management	3	397	12,748	13,145	11,621
Conference Centre	3	569	2,030	2,599	1,776
		966	14,778	15,744	13,397
Other incoming resources					
Interest		-	36	36	-
Total incoming resources		966	14,814	15,780	13,397
RESOURCES EXPENDED					
Charitable activities					
Provision of Facilities Management	4	612	12,932	13,544	12,426
Conference Centre	4	-	1,877	1,877	1,680
Governance costs					
	5	-	13	13	13
Total resources expended		612	14,822	15,434	14,119
Net income / (expenditure) for the year		354	(8)	346	(722)
Fund balances at start of year		22,813	1,202	24,015	24,737
Fund balances at end of year		23,167	1,194	24,361	24,015

The notes on pages 9 to 12 form part of these Financial Statements.

There are no other gains or losses apart from those recognised above.

All activities are continuing.

Hinxton Hall Limited
Balance Sheet
As at 30 September 2008

		2008	2007
		Total	Total
	Note	£'000	£'000
Tangible fixed assets	7	24,361	24,015
Current assets			
Debtors	8	2,205	2,558
Cash at bank		625	139
		2,830	2,697
Current liabilities			
Creditors: amounts falling due within one year	9	2,830	2,697
Net current assets		-	-
Net assets		24,361	24,015
Funds			
Restricted Building Fund	10	23,167	22,813
Unrestricted General Fund	10	1,194	1,202
		24,361	24,015

The Financial Statements on pages 7 to 12 were approved by the Board of Directors on 19th November 2008 and signed on its behalf by:



J Cooper
Chairman

Hinxton Hall Limited
Notes to the Financial Statements
For the year ended 30 September 2008

1. ACCOUNTING POLICIES

a) Basis of Preparation

The Financial Statements are prepared under the historical cost convention and in accordance with applicable UK accounting standards. In particular they comply with the Charities Act 1993, the Statement of Recommended Practice 'Accounting and Reporting by Charities' (SORP), published in March 2005 and the Companies Act 1985.

b) Accounting Policies

Accounting Policies have been reviewed in accordance with FRS 18 "Accounting Policies".

c) Cash Flow Statement

The Company is a wholly-owned subsidiary of The Wellcome Trust Limited, as Trustee of the Wellcome Trust, and is included in the Consolidated Financial Statements of the Wellcome Trust, which are publicly available. Consequently the Company has taken advantage of the exemption from preparing a cash flow statement in accordance with FRS 1 (revised) "Cash Flow Statements".

d) Grants

Grants awarded are recognised in the Statement of Financial Activities when receivable.

e) Fund Accounting

The Building Fund represents grants received from the Wellcome Trust specifically for the construction of buildings on the Genome Campus. It is a restricted fund under the terms of the grant.

The General Fund is an unrestricted fund and represents any funds acquired for the general use of the Company. Income and costs relating to the provision of site services and conference facilities are reflected in this fund.

f) Fixed Assets

Fixed assets are stated at cost less accumulated depreciation.

Depreciation is charged on assets in use on a straight-line basis as follows:

Major plant and machinery	7%
South Field furniture and fittings	10%
Other furniture and fittings	20%
Standard plant and machinery	20%
Motor vehicles	25%
Computers and office equipment	33%

All expenditure on the acquisition, creation or enhancement of fixed assets is capitalised on an accruals basis, subject to a de minimis threshold of £5,000, this has increased from the prior year figure of £1,000 in line with the Wellcome Trust group policy. Depreciation is charged on assets in use from the commencement of the month in which they are brought into use. Leasehold Land and Buildings, which are leased at a £nil annual cost from the Wellcome Trust, are amortised over the life of the lease (50 years, expiring 9 September 2045). Impairment reviews are undertaken when, in the opinion of the Directors, events or circumstances have arisen which indicate that the carrying value of an asset is impaired.

g) Finance Leases

Assets acquired under finance leases are capitalised and depreciated over the life of the finance leases. The finance leases detailed in the fixed assets note (see note 7) are in connection with various items of plant, equipment and vehicles. These assets are purchased by contractors who provide other services for the Company. The contractors buy the assets during the term of the contract and these assets then become the property of the Company at the end of the contract. The cost of the finance lease is not separately identifiable from the total contract sum for the services provided from the contractors.

h) Resources Expended

The costs of charitable expenditure are allocated according to the area of the Company's activities to which the expenditure relates.

All expenditure is included in the Statement of Financial Activities in accordance with the accruals concept.

The cost of providing conference centre facilities is partly charged to Wellcome Trust Trading Limited ("WTTL"). WTTL uses the venue to provide conference centre facilities for conferences falling outside the primary purpose of the Company.

Hinxton Hall Limited
Notes to the Financial Statements (continued)
For the year ended 30 September 2008

2. DIRECTORS' EMOLUMENTS AND EXPENSES

No Directors received any emoluments or expenses in respect of their services as Directors to the Company.

3. CHARITABLE ACTIVITIES – INCOMING RESOURCES

	Restricted Building Fund	Unrestricted General Fund	2008 Total	2007 Total
	£'000	£'000	£'000	£'000
Provision of Facilities Management				
Service charges	-	12,405	12,405	10,800
Capital Grants from the Wellcome Trust	397	165	562	137
Revenue Grants from the Wellcome Trust	-	178	178	684
	397	12,748	13,145	11,621
Conference Centre				
Conference Centre sales	-	1,704	1,704	1,453
Capital Grants from the Wellcome Trust	569	153	722	96
Revenue Grants from the Wellcome Trust	-	173	173	227
	569	2,030	2,599	1,776

4. CHARITABLE ACTIVITIES – RESOURCES EXPENDED

	Restricted Building Fund	Unrestricted General Fund	2008 Total	2007 Total
	£'000	£'000	£'000	£'000
Provision of Facilities Management	612	12,932	13,544	12,426
Conference Centre costs	-	1,877	1,877	1,680
	612	14,809	15,421	14,106
Total expenditure above also includes :				
Depreciation				
Provision of Facilities Management	612	240	852	904
Conference Centre costs	-	80	80	51
	612	320	932	955
Finance Support Costs				
Provision of Facilities Management	-	93	93	91
Conference Centre costs	-	31	31	31
	-	124	124	122

The finance support costs are allocated based on time spent on each activity.

5. GOVERNANCE COSTS

The audit fee, excluding VAT, for the year was £13,000 (2007: £13,000).

6. STAFF COSTS

The Company has no employees, with services provided being sub-contracted from third parties. The management and administration of the Company is undertaken by staff seconded from The Wellcome Trust Limited, as Trustee of the Wellcome Trust.

Hinxton Hall Limited
Notes to the Financial Statements (continued)
For the year ended 30 September 2008

7. TANGIBLE FIXED ASSETS

	Leasehold Land and Buildings	Plant, Equipment and Vehicles	Office Equipment and Computers	Furniture and Fittings	Assets in the course of construction	Total
	£'000	£'000	£'000	£'000	£'000	£'000
Cost as at 1 Oct 2007	27,369	1,395	587	1,592	-	30,943
Reclassification	-	455	(184)	(271)	-	-
Additions	397	139	58	120	569	1,283
Disposals	-	(265)	(183)	(400)	-	(848)
Cost as at 30 Sept 2008	27,766	1,724	278	1,041	569	31,378
Depreciation as at 1 Oct 2007	(4,556)	(895)	(466)	(1,011)	-	(6,928)
Reclassification	-	(369)	135	234	-	-
Charge for the year	(612)	(167)	(58)	(100)	-	(937)
Eliminated on disposal	-	265	183	400	-	848
Depreciation as at 30 Sept 2008	(5,168)	(1,166)	(206)	(477)	-	(7,017)
Net book value as at 30 Sept 2008	22,598	558	72	564	569	24,361
Net book value as at 30 Sept 2007	22,813	500	121	581	-	24,015

Opening figures have been reclassified to correctly show the analysis of the cost and net book value of plant, equipment, office equipment and fixtures and fittings.

Included within Plant, Equipment and Vehicles are assets held under finance leases. These assets cost £75,000 (2007: £133,000) with related accumulated depreciation of £43,000 (2007: £90,000) of which £11,000 has been charged in this accounting period (see note 11).

8. DEBTORS

	2008	2007
	£'000	£'000
Trade debtors	533	459
Net amount due from Wellcome Trust group entity	1,122	1,593
Other debtors	42	101
Prepayments and accrued income	508	405
	2,205	2,558

9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2008	2007
	£'000	£'000
Trade creditors	1,251	1,313
Loan from Wellcome Trust group entity	176	214
Accruals and deferred income	1,403	1,170
	2,830	2,697

Hinxton Hall Limited
Notes to the Financial Statements (continued)
For the year ended 30 September 2008

9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR (CONTINUED)

The loan from Wellcome Trust group entity is due to Wellcome Trust Trading Limited and is unsecured and interest bearing at a rate varying from 2.0% to 2.5%. It is payable on request from Wellcome Trust Trading Limited.

10. FUND MOVEMENTS

	Building	General
	£'000	£'000
Balance as at 1 October 2007	22,813	1,202
Incoming resources	966	14,814
Resources expended	(612)	(14,822)
Balance as at 30 September 2008	23,167	1,194

11. OBLIGATIONS UNDER FINANCE LEASES

Included in accruals and deferred income are obligations under finance leases as follows:

	2008	2007
	£'000	£'000
Within 1 year	11	11
Within 2 to 5 years	21	32
	32	43

12. RELATED PARTY TRANSACTIONS

The Company has taken advantage of the exemption contained in FRS 8 "Related Party Disclosures", which exempts it from disclosing details of transactions with the Wellcome Trust and its subsidiaries, as the Company is a wholly-owned subsidiary of The Wellcome Trust Limited, as Trustee of the Wellcome Trust.

13. CONTROLLING ENTITY AND EXEMPTIONS

The Company is a charity registered in England with the Charity Commission (Charity registration number 1048066) and a company limited by guarantee and registered in England (Company number 3062160). The members of the Company are The Wellcome Trust Limited (as Trustee of the Wellcome Trust) and Genome Research Limited. The Company is considered to be a wholly-owned subsidiary of the Wellcome Trust for accounting purposes. In the event of the Company being wound up, the liability in respect of the guarantee is limited to £1 per member.

The Directors regard the Wellcome Trust as the ultimate controlling party.

Copies of the Wellcome Trust Annual Report and Financial Statements 2008 are available from the Trust's website (www.wellcome.ac.uk/aboutus) or, without charge, from:

The Wellcome Trust
 FREEPOST
 ANG 6754
 Ely CB7 4YE

Hinxton Hall Limited Administrative Details

Registered Company Number

3062160

Registered Office

215 Euston Road
London
NW1 2BE

Principal Address

Wellcome Trust Genome Campus
Hinxton
Cambridgeshire
CB10 1RQ

Directors

J Cooper (*Chairman*)
G Kiff
D Davison

Company Secretary

J Stewart

Registered Auditors

PricewaterhouseCoopers LLP
Hay's Galleria
1 Hay's Lane
London
SE1 2RD

Bankers

National Westminster Bank plc
King's Parade Branch
Bene't Street
Cambridge
CB2 3PU

Solicitors

CMS Cameron McKenna
Mitre House
160 Aldersgate Street
London
EC1A 4DD